MedTrace Logo

Seven-year Outcomes Following Intensive Anti-VEGF Therapy in Wet AMD

NCT05678517 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 47

Last updated 2023-01-10

No results posted yet for this study

Summary

The aim of this study was to assess long-term benefits of intensive aflibercept and ranibizumab anti-VEGF therapy in patients with exudative AMD.

Conditions

  • Age-Related Macular Degeneration

Interventions

DRUG

Anti-VEGF

intravitreal ranibizumab or intravitreal aflibercept

Sponsors & Collaborators

  • Semmelweis University

    lead OTHER

Principal Investigators

  • Andras Papp, MD, PhD · Semmelweis University

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-01
Primary Completion
2017-12-31
Completion
2022-12-06
FDA Drug
Yes

Countries

  • Hungary

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05678517 on ClinicalTrials.gov